|
TargetMol
stat1 ![]() Stat1, supplied by TargetMol, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/recombinant+human+stat1/STAT1+Protein%2C+Human%2C+Recombinant/pm40139835-65-2-3 Average 93 stars, based on 1 article reviews
stat1 - by Bioz Stars,
2026-11
93/100 stars
|
Buy from Supplier |
|
OriGene
stat1 ![]() Stat1, supplied by OriGene, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/recombinant+human+stat1/STAT1+(NM_007315)+Human+Recombinant+Protein/pm35768435-289-22-27 Average 91 stars, based on 1 article reviews
stat1 - by Bioz Stars,
2026-11
91/100 stars
|
Buy from Supplier |
|
ABclonal Biotechnology
recombinant human stat1 protein ![]() Recombinant Human Stat1 Protein, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/recombinant+human+stat1/Recombinant+human+STAT1+Protein/pmc13066370-435-0-4 Average 94 stars, based on 1 article reviews
recombinant human stat1 protein - by Bioz Stars,
2026-11
94/100 stars
|
Buy from Supplier |
|
Creative BioMart
recombinant stat1 ![]() Recombinant Stat1, supplied by Creative BioMart, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/recombinant+human+stat1/Recombinant+Human+STAT1/pm42547268-295-31-33 Average 94 stars, based on 1 article reviews
recombinant stat1 - by Bioz Stars,
2026-11
94/100 stars
|
Buy from Supplier |
|
Recombinant Human STAT1 (P42224-2) isoform beta (Met 1-Val 712), fused with the N-terminal polyhistidine-tagged GST tag, was produced in Baculovirus-Insect cells.http://www.creativebiomart.net/description_108298_12.htm
|
Buy from Supplier |
|
Human STAT1 Recombinant Protein Tag Free Lyophilized from Innovative Research has been recombinantly produced in E. coli. This is a Lyophilized protein buffered in Lyophilized from a 0.2 um filtered solution of 20mM PB,150mM NaCl,pH7.4.
|
Buy from Supplier |
|
The Recombinant Human STAT1 Protein from Novus Biologicals is derived from E coli The Recombinant Human STAT1 Protein has been validated for the following applications SDS Page
|
Buy from Supplier |
|
STAT1; Recombinant Human STAT1; Recombinant Human STAT1
|
Buy from Supplier |
Image Search Results
Journal: Journal for immunotherapy of cancer
Article Title: Orlistat facilitates immunotherapy via AKT-FOXO3a-FOXM1-mediated PD-L1 suppression.
doi: 10.1136/jitc-2024-008923
Figure Lengend Snippet: Figure 3 Orlistat suppressed PD-L1 via inhibition of FOXM1 signaling. (A) Volcano plot of the expression of the reported transcription factors that regulated the expression of PD-L1. These TFs include STAT1, ATF3, IRF2, TFEB, IRF1, YY1, STAT3, JUN, HSF1, NFκB, SP1, FOXP3, BRD4, EZH2, MYC, HIF-1α, and FOXM1. (B, C) qRT-PCR measurement of mRNA expression of FOXM1 after orlistat (40 µM) treatment for 0 hour, 24 hours, or 48 hours in AGS and HCT116 (B), MC38 and CT26 cells (C). (D) WB analysis of FOXM1 protein levels after orlistat treatment for different times (0 hour, 24 hours, 48 hours) in AGS, HCT116, MC38, and CT26 cells. (E) Representative images of immunohistochemical staining of FOXM1 protein expression in resected tumors at day 25. Scale bar=50 µm. (F) The expression of PD-L1 mRNA in AGS and MC38 cells after transfection with FOXM1 overexpression or knockdown. (G) WB for PD-L1 protein levels after FOXM1 overexpression or knockdown in AGS and MC38 cells. (H) Schematic representation of the PD-L1 gene promoter regions and primer pairs used for ChIP assays. (I) ChIP-qPCR assay was used to detect the binding of FOXM1 to the PD-L1 promoter at the (+222 to +450 bp) region in AGS cells. (J) ChIP-qPCR analysis of the impact of orlistat (40 µM) on the binding of FOXM1 to the PD-L1 promoter. (K) The luciferase activity of PD-L1 promoter after FOXM1 overexpression with or without orlistat (40 µM). HEK293T cells in 24-well plates were transfected with FOXM1 plasmids or control. The luciferase activity was measured 36 hours later. *p<0.05, **p<0.01, ***p<0.001.
Article Snippet: Following activation,
Techniques: Inhibition, Expressing, Quantitative RT-PCR, Immunohistochemical staining, Staining, Transfection, Over Expression, Knockdown, ChIP-qPCR, Binding Assay, Luciferase, Activity Assay, Control
Journal: Journal for immunotherapy of cancer
Article Title: Orlistat facilitates immunotherapy via AKT-FOXO3a-FOXM1-mediated PD-L1 suppression.
doi: 10.1136/jitc-2024-008923
Figure Lengend Snippet: Figure 8 Orlistat upregulates ISGs and MHC-I through activating the STAT1 pathway. (A) Gene set enrichment plots of the antigen processing and presentation hallmarks. (B) Gene set enrichment plots of the JAK-STAT signaling pathway hallmarks. (C–E) WB analysis of Y701-phosphorylated STAT1 (p-STAT1-701) and total STAT1 in AGS and MC38 cells at different times (C) and concentrations (D) after orlistat administration, and tumors collected from mice-bearing subcutaneous MC38 tumors with or without orlistat treatment (E). (F–K) Quantitative PCR analysis of mRNA expression of IFNα, IFNβ, and ISGs or antigen processing and presentation genes in purified MC38 syngeneic tumors cells treated with control or orlistat (F), MC38 (H, I), and AGS (J, K) cell lines. (L) IB analysis and quantitative data of STAT1 in DMSO control vs orlistat-treated cells. AGS cells were treated with cycloheximide (CHX) 100 mg/mL, and collected at the indicated times. (M) Orlistat administration (40 µM) increased the thermal stability of STAT1 protein as determined by thermal stability shift assay (n=3). (N, O) SPR sensorgrams (N) and steady-state curves (O) for the orlistat analyte (2-fold dilutions; 50–1.56 µM) binding to the STAT1 protein ligand. (P) Schematic diagram depicting orlistat-mediated inhibition of PD-L1 expression in gastric cancer and colon cancer cells and promoting the expression of ISGs and MHC-I **p<0.01, ***p<0.001.
Article Snippet: Following activation,
Techniques: Real-time Polymerase Chain Reaction, Expressing, Control, Shift Assay, Binding Assay, Inhibition
Journal: Nature Communications
Article Title: Targeting leucine-rich repeat kinase 2 overcomes resistance to oncolytic herpes simplex virus-based therapies in glioblastoma
doi: 10.1038/s41467-026-70132-9
Figure Lengend Snippet: a A scatter plot showing differential gene expression in oHSV-GFP-infected U-251 MG cells treated with or without LRRK2-IN-1 (LRRK2i). U-251 MG cells were pretreated with LRRK2i (2.5 µM) or left untreated for 4 h, followed by infection with oHSV-GFP (MOI = 0.25 PFU/cell) for 4 h. RNA-Seq was used to assess differentially expressed genes among the treated cells. Blue dots represent genes significantly downregulated by LRRK2i during infection, and red dots represent genes significantly upregulated by LRRK2i during infection. b A heatmap showing the expression patterns of differentially expressed genes belonging to the “response to virus” category. The normalized expression values (Log 2 (TPM + 1)) in the heatmap depict the mean across three biological replicates. c GO enrichment analysis showing the top eight most enriched pathways downregulated by LRRK2i in oHSV-GFP-infected U-251 MG cells. d U-251 MG and U-87 MG cell lines were treated with LRRK2-IN-1 (2.5 μM) for 4 h, followed by IFNα and anti-IFNR1 (α-IFNR1) for an additional 4 h, and then infected with oHSV-GFP (MOI = 0.25 PFU/cell). Cell viability was determined 48 h post-infection. e Western blot analysis of p-STAT1, STAT1, and β-actin in GBM cell lines infected with oHSV-GFP or mock-infected, either with or without LRRK2-IN-1 (2.5 µM), 48 h post-infection. IFNα served as a positive control. The samples derive from the same experiment but different gels for p-STAT1, another for STAT1 and another for actin were processed in parallel. f p-STAT1 and STAT1 expression levels were quantified by densitometric analysis of bands from three independent Western blot experiments corresponding to Fig. 4e. g RT‒qPCR analysis of the expression of the indicated IFN-stimulated gene transcript expression in GBM cell lines infected with oHSV-GFP or mock-infected, either with or without LRRK2-IN-1 (2.5 µM), 12 h post-infection. h Western blot analysis of the indicated IFN-stimulated proteins (IFI16 and IRF9) in GBM cell lines infected with oHSV-GFP or mock-infected, either with or without LRRK2-IN-1 (2.5 µM), 48 h post-infection. IFI16 and IRF9 expression levels were quantified by densitometric analysis of bands from three independent Western blot experiments. The samples derive from the same experiment but different gels for IFI16, another for IRF9 and another for actin were processed in parallel. The data are presented as the mean ± SD from two independent experiments ( d ) or three independent experiments ( d , f – h ), and P values were calculated using an ordinary one-way ANOVA ( d , f – h ).
Article Snippet:
Techniques: Gene Expression, Infection, RNA Sequencing, Expressing, Virus, Western Blot, Positive Control
Journal: Nature Communications
Article Title: Targeting leucine-rich repeat kinase 2 overcomes resistance to oncolytic herpes simplex virus-based therapies in glioblastoma
doi: 10.1038/s41467-026-70132-9
Figure Lengend Snippet: a Anti-myc immunoprecipitates prepared from 293 T cells transfected with the indicated plasmids were subjected to SDS‒PAGE and blotted with the indicated antibodies. The samples derive from the same experiment but different gels for Myc and another for STAT1 were processed in parallel. b Endogenous LRRK2 and STAT1 complexes in U-118 MG cells were isolated by co-immunoprecipitation (co-IP) and detected using anti-LRRK2 antibodies. The samples derive from the same experiment but different gels for LRRK2 and another for STAT1 were processed in parallel. c The interactions between STAT1-Flag and Myc-LRRK2 mutants were detected by a co-IP assay. FL, full-length. The samples derive from the same experiment but different gels for Myc and another for Flag were processed in parallel. d , e The interactions between Myc-LRRK2 and STAT1-HA truncations were detected by a co-IP assay. The samples derive from the same experiment but different gels for Myc and another for HA were processed in parallel. f STAT1-His proteins were incubated with human FL LRRK2 proteins in the presence of ATP. The reaction products were analyzed with the indicated antibodies. CD300A proteins served as a negative control. The samples derive from the same experiment but different gels for Flag and another for His were processed in parallel. g , h 293 T cells were cotransfected with Flag-STAT1 and LRRK2 in the presence or absence of LRRK2-IN-1, and the phosphorylation of STAT1 was analyzed by western blot analysis. The samples derive from the same experiment but different gels for STAT1, another for p-STAT1 701 and another for p-STAT1 727 were processed in parallel. i 293 T cells were cotransfected with Flag-STAT1 and each LRRK2 mutant, either in the presence or absence of LRRK2-IN-1, and STAT1 phosphorylation was assessed via western blot analysis. The samples derive from the same experiment but different gels for STAT1, another for p-STAT1 701 and another for GAPDH were processed in parallel. j Western blotting was performed to assess and quantify phosphorylated STAT1 and HSV-derived GFP in U-87 MG cells treated with fludarabine (10 µM) for 4 h, either in the presence or absence of LRRK2-IN-1, followed by infection with oHSV-GFP (MOI = 1 PFU/cell). The samples derive from the same experiment but different gels for STAT1 and GFP, another for p-STAT1 701 and another for actin were processed in parallel. k Western blotting was performed to assess and quantify phosphorylated STAT1 and HSV-derived GFP in GBM-1 cells. Cells transfected with EV, LRRK2 or LRRK2 D1994A were infected with oHSV-GFP (MOI = 0.5 PFU/cell), with or without LRRK2-IN-1. The samples derive from the same experiment but different gels for STAT1 and GFP, another for p-STAT1 701 and another for actin were processed in parallel. l Western blotting was performed to assess and quantify phosphorylated TBK1, phosphorylated LRRK2, phosphorylated Rab10, and phosphorylated STAT1 in BX795 (10 µM)-treated U-87 cells following infection with oHSV-GFP (MOI = 0.5 PFU/cell). The samples derive from the same experiment but different gels for p-TBK1, another for p-LRRK2, another for LRRK2, another for p-Rab10 and p-STAT1, another for STAT1 and another for actin were processed in parallel. Western blot analyses were independently repeated twice for panels ( a – d and f )and three times for panels ( e , g and i – l ), with similar results. The data are presented as the mean ± SD from three independent experiments ( h – l ), and P values were calculated using an ordinary one-way ANOVA ( h – l ).
Article Snippet:
Techniques: Transfection, Isolation, Immunoprecipitation, Co-Immunoprecipitation Assay, Incubation, Negative Control, Phospho-proteomics, Western Blot, Mutagenesis, Derivative Assay, Infection